Part II: The Product Lifecycle

Testing & Clinical Validation

Ensuring your product works and meets clinical standards
View as Markdown

Testing in health products spans multiple dimensions — from software quality to clinical efficacy. Each type of testing serves a different purpose and may be required by regulators.

Testing Types in Health

TypeWhat It ValidatesRegulatory Relevance
Unit testingIndividual components work correctlyIEC 62304 software lifecycle
Integration testingComponents work togetherRequired for all medical device software
System testingFull system meets requirementsSubmission evidence
Usability testingUsers can complete tasks safelyFDA requires for all devices
Clinical testingProduct improves health outcomesRequired for most SaMD submissions
Security testingSystem resists attacksHIPAA, GDPR, SOC 2
Performance testingSystem handles expected loadDeployment requirement
Accessibility testingSystem works for all abilitiesWCAG compliance, EAA

Regulatory Testing Requirements

Software as a Medical Device (SaMD) requires specific testing evidence:

FDA (US) :

  • 510(k): Substantial equivalence testing to predicate device
  • De Novo: Safety and effectiveness evidence
  • PMA: Clinical trial data required
  • Usability validation per IEC 62366

EU MDR:

  • Clinical evaluation per MEDDEV 2.7/1 Rev.4
  • Performance evaluation for IVDs
  • Usability testing per IEC 62366-1
  • Software lifecycle per IEC 62304

Usability Validation

FDA requires usability testing with representative users performing critical tasks:

  • Formative testing: Early iterative testing to identify issues
  • Summative validation: Final testing to demonstrate safe use
  • Use error analysis: Identifying potential use errors and mitigations
  • Labeling comprehension: Can users understand instructions?

Clinical Trials vs. Real-World Evidence

ApproachWhen to UseTimeline
Randomized controlled trialRegulatory submissions, high-risk devices12-36 months
Pragmatic trialReal-world effectiveness, reimbursement evidence6-18 months
Single-arm studyInitial efficacy signal, feasibility3-12 months
Real-world evidencePost-market surveillance, payer evidenceOngoing